Pharma BD Deal Intelligence
GEN highlighted Specifar's generic Nexium as the marquee asset, with up to €40M in contingent payments over five years post-launch tied to esomeprazole…
Watson's 8-K exhibit characterizes the Specifar acquisition as strengthening its global generic product development and European commercial platform, with…
Trade outlet reports Watson's acquisition of Specifar, summarizing the cash-plus-contingent-consideration structure and Specifar's third-party product…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Watson acquired Greek branded-generics developer Specifar for €400M (~$562M) cash plus contingent consideration of up to €40M (~$56M) tied to esomeprazole profits. Closed May 25, 2011. Strengthened Watson's European generics platform.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Specifar Pharmaceuticals S.A. (this deal) | 2011 | $562M | 44 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
← Browse all deals · How we score deals
More: 2011 deals · Watson Pharmaceuticals (Actavis Inc.) deals · Other deals